|
OSLO, Norway, May 9, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2019 results. A meeting for investors, analysts and press will take place in Oslo ... |
